Essais liés2clinical trials
VilleBydgoszczlocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06602479

Ouvrir le site du centre

Essais cliniques associés

2
MoléculeIndication / populationPhaseNCTTitreStatut
Rimegepant 75mg daily dosing Migraine Phase 4 NCT05217927 Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens COMPLETED
MEDI0618 Migraine Phase 2 NCT06602479 AURORA — A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine RECRUITING